Lurasidone (Latuda)​

Lurasidone (Latuda) is an atypical antipsychotic used primarily to treat schizophrenia and bipolar disorder (depressive episodes). It is known for its favorable metabolic profile and low sedation compared to other antipsychotics. Here’s a detailed breakdown of Lurasidone's mechanism of action, benefits, side effects, and dosage.

Mechanism of Action:Lurasidone has a multi-receptor mechanism that involves several neurotransmitter systems, which makes it effective in treating both psychotic symptoms and mood symptoms:
  • Dopamine Receptor Activity:
    Lurasidone is a D2 receptor antagonist, meaning it blocks dopamine receptors to help control the positive symptoms of schizophrenia (e.g., hallucinations, delusions).
    • It also acts as a partial agonist at dopamine D2 receptors, which may help reduce the risk of extrapyramidal symptoms (EPS) compared to older antipsychotics.
  • Serotonin Receptor Activity:
    Lurasidone is a 5-HT2A antagonist, which helps improve the negative symptoms of schizophrenia (e.g., lack of motivation, emotional blunting). It also has partial agonist effects at 5-HT1A receptors, contributing to antidepressant-like effects.
  • Effect on Other Receptors:
    Lurasidone also interacts with alpha-1 adrenergic receptors (which can cause sedation or orthostatic hypotension) and histamine H1 receptors (which may contribute to mild sedation).
  • Benefits:
  • Schizophrenia:
    Lurasidone is FDA-approved for the treatment of schizophrenia in adults and adolescents (ages 13-17). It is effective in treating positive (e.g., hallucinations, delusions) and negative (e.g., lack of emotion, social withdrawal) symptoms.
  • Bipolar Depression:
    Lurasidone is also approved for bipolar depression (depressive episodes associated with bipolar I disorder), both as monotherapy and in combination with lithium or valproate.
    • It is particularly useful for treating depressive episodes in bipolar disorder without causing significant mania or weight gain, unlike other medications.
  • Low Sedation and Metabolic Profile:
    Lurasidone is considered to have a low risk of metabolic side effects, such as weight gain, increased blood sugar, and increased cholesterol compared to many other atypical antipsychotics. It also carries a lower risk for sedation and cognitive impairment.

  • Dosage:
  • Schizophrenia (Adults):
    • Initial dose: Start with 40 mg once daily.
    • Maintenance dose: 40 mg to 160 mg daily based on response and tolerability.
    • It is typically taken once a day with food (at least 350 calories for optimal absorption).
  • Bipolar Depression (Adults):
    • Initial dose: 20 mg once daily.
    • Maintenance dose: 20 mg to 120 mg daily depending on individual response.
    • Like schizophrenia, it is taken once daily with food.
  • Pediatric Schizophrenia (Ages 13-17):
    • Initial dose: Start with 40 mg once daily.
    • Maintenance dose: Typically 40 mg to 80 mg daily.
  • Maximum Dose: 160 mg/day for both schizophrenia and bipolar depression.

    Side Effects:
  • Common Side Effects:
    • Sedation or drowsiness: Occurs in 10-15% of patients.
    • Akathisia (restlessness): Reported in about 10-15% of patients.
    • Nausea: Affects around 10% of patients.
    • Insomnia: Reported by 5-10% of patients.
    • Weight gain: Minimal weight gain compared to other antipsychotics. Approximately 3-5% of patients report slight weight gain.
    • Headache: Occurs in 5-10% of patients.
  • Serious Side Effects:
    • Extrapyramidal Symptoms (EPS): These can include tremors, rigidity, and bradykinesia, although the incidence is lower than older antipsychotics. EPS occurs in less than 5% of patients.
    • Tardive Dyskinesia (TD): A rare but serious side effect (less than 1% of patients) characterized by involuntary, repetitive movements.
    • Neuroleptic Malignant Syndrome (NMS): A rare, life-threatening condition marked by fever, muscle rigidity, and altered mental status.
    • Elevated Prolactin Levels: Lurasidone has a lower risk of causing prolactin elevation compared to other atypicals, but it still occurs in 1-2% of patients.
    • Orthostatic Hypotension: Some patients may experience a drop in blood pressure when standing, which can lead to dizziness or fainting.
  • Metabolic Effects:
    • Low risk of weight gain compared to other atypical antipsychotics, with about 3-5% of patients experiencing weight gain.
    • Low risk of elevated blood glucose and cholesterol compared to drugs like olanzapine or quetiapine.

  • Prevalence of Side Effects:
  • Sedation/Drowsiness: Affects approximately 10-15% of patients.
    • Nausea: About 10% of patients report nausea.
    • Akathisia (restlessness): Seen in 10-15% of patients.
    • Weight gain: Approximately 3-5% of patients may experience slight weight gain.
    • Extrapyramidal Symptoms (EPS): Occurs in less than 5% of patients.

  • Summary:Lurasidone (Latuda) is an atypical antipsychotic with a dual mechanism of action that includes dopamine and serotonin receptor modulation. It is effective for treating schizophrenia and bipolar depression, offering benefits like low sedation and minimal metabolic side effects. Common side effects include sedation, nausea, and restlessness (akathisia), while more serious side effects such as tardive dyskinesia and neuroleptic malignant syndrome are rare. The typical dosing for schizophrenia starts at 40 mg daily and can go up to 160 mg/day, while for bipolar depression, the starting dose is 20 mg daily.